(1) The drugs selected for analysis appear on the Analysis Results screen in bold-faced text and in alphabetical order. Under each drug is a list of other selected drugs with which it may interact (or for which data exists in the database describing a lack of interaction; ie, risk rating = [A]). Therefore, a potential interaction will appear under each drug of a potential interacting pair. Both entries lead to the same interaction monograph/data. Various formats for data presentation were considered. This format was chosen in recognition that most drug regimen changes occur as an addition of a single drug (versus multiple drugs). In such circumstances, the potential interactions-of-concern relate to the most recently added drug to the regimen. The Analysis Results screen allows Users to quickly find the added drug, and identify any potential interactions with others in the drug list.

(2) At times, an interacting drug name may appear multiple times under the same bold-faced drug. Many potentially interacting drug pairs are identified based on theoretical, pharmacology (mechanism)-based assessments alone (eg, cytochrome P450 enzyme profile, serotonergic activity, QTc-prolonging activity). If more than one potential mechanism might contribute to an interaction, the interacting drug will be listed multiple times – once for each plausible mechanism. Each appearance of an interacting drug name under a single bold-faced entry will lead to a different monograph/data describing the potential interaction. The net outcome of multiple theoretical mechanisms is nearly impossible to qualify or quantify in the absence of objective data. If objective data has been reported for an interacting pair (eg, case report or pharmacokinetic study), a unique, drug (or class)-specific monograph will be presented in lieu of the multiple theoretical monographs.